CBMX - CombiMatrix Corporation

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
6.25
0.00 (0.00%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close6.25
Open6.55
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.11 - 6.60
52 Week Range2.60 - 8.20
Volume51,819
Avg. Volume44,256
Market Cap18.399M
Beta1.65
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Researchlast month

    CBMX: Results Remain Very Strong, Despite Record Revenue Streak Ending

    By Brian Marckx, CFA NASDAQ:CBMX Q3 2017:  Results Remain Very Strong, Despite Record Revenue Streak Ending… CombiMatrix (NASDAQ:CBMX) reported financial results for Q3.  While financial results remained ...

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017
    Capital Cube4 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017

    Categories: Yahoo FinanceGet free summary analysis CombiMatrix Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of CombiMatrix Corp. – Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, NeoGenomics, Inc. and RadNet, Inc. (DGX-US, LH-US, NEO-US and RDNT-US) that have also reported for this period. Highlights ... Read more (Read more...)

  • CombiMatrix shares jump on buyout news
    Investing.com5 months ago

    CombiMatrix shares jump on buyout news

    Investing.com - Shares of CombiMatrix Corp (NASDAQ:CBMX) rallied on Tuesday and were up about 40% on the home stretch to the closing bell with investors cheering a proposed merger of the company with InVitae Corp (NYSE:NVTA)

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 29, 2017
    Capital Cube7 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 29, 2017

    Categories: Yahoo FinanceGet free summary analysis CombiMatrix Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of CombiMatrix Corp. – Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, NeoGenomics, Inc., RadNet, Inc. and Transgenomic, Inc. (DGX-US, LH-US, NEO-US, RDNT-US and TBIO-US) that have also reported for ... Read more (Read more...)

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of CBMX earnings conference call or presentation 4-May-17 8:30pm GMT

    Q1 2017 CombiMatrix Corp Earnings Call

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
    Capital Cube9 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017

    Categories: Yahoo Finance Get free summary analysis CombiMatrix Corp. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of CombiMatrix Corp. – Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Enzo Biochem, Inc., NeoGenomics, Inc. and RadNet, Inc. (DGX-US, LH-US, ENZ-US, NEO-US and RDNT-US) that have also reported ... Read more (Read more...)

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: 2016 By the Numbers : March 13, 2017
    Capital Cube9 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: 2016 By the Numbers : March 13, 2017

    Categories: Yahoo Finance Get free summary analysis CombiMatrix Corp. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of CombiMatrix Corp. – Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings and NeoGenomics, Inc. (DGX-US, LH-US and NEO-US) that have also reported for this period. Highlights Gross margins widened ... Read more (Read more...)

  • Zacks Small Cap Research10 months ago

    CBMX: Q4 Records On Almost Every Measure

    Some things only change for the better.  That continues to be the story with CombiMatrix’s (CBMX) operational and financial results.  The company reported Q4 earnings last week which set new records on revenue, gross margin, profitability and cash collections.  The strong financial performance was largely the product of their bread-and-butter reproductive health microarray portfolio (i.e. As we have noted in the past, the company’s financial performance is a direct result of execution of management’s strategy.  CBMX has been actively engaged in their fate by targeting geographic areas with favorable reimbursement, sponsoring or otherwise supporting evidence-based studies, communicating with payers and optimizing their product portfolio to include cash-pay products.  The company’s recent implementation of a new compensation model and other efficiency initiatives has resulted in a rapid and substantial shedding of expenses.  And favorable changes in payers’ coverage decisions, CBMX’s investments in billing and collections resources, sales force training and their deft updates to their product portfolio have contributed to margin expansion and greatly improved cash collections.

  • Zacks Small Cap Research10 months ago

    CBMX:Expect Record Revenue, Profit in 2017 On Strong Fundamentals

    Through the first nine months of 2016 CombiMatrix’s (CBMX) revenue is up 26%, gross margin is 800 basis points wider, operating loss is 28% lower and EBITDA loss is improved by almost 38% as compared to the same period in 2015.  As we have recently noted, we characterize the improved financial performance as ‘high quality’ and what reasonably could be expected to be replicable given that these are the products of CombiMatrix’s direct efforts and/or favorable changes in industry fundamentals. CBMX has been actively engaged in their fate by targeting geographic areas with favorable reimbursement, sponsoring or otherwise supporting evidence-based studies, communicating with payers and optimizing their product portfolio to include cash-pay products.  The company’s recent implementation of a new compensation model and other efficiency initiatives has resulted in a rapid and substantial shedding of expenses.  And favorable changes in payers’ coverage decisions, CBMX’s investments in billing and collections resources and their deft updates to their product portfolio have contributed to margin expansion and greatly improved cash collections.